Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases—A Clinical Practice Update: Commentary

2019 ◽  
Vol 156 (1) ◽  
pp. 36-42 ◽  
Author(s):  
Stephen B. Hanauer ◽  
William J. Sandborn ◽  
Gary R. Lichtenstein
Keyword(s):  
Clinical Practice ◽  
Inflammatory Bowel Diseases ◽  
Thiopurine Therapy ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals Mycophenolate mofetil following intolerance or failure of thiopurine therapy in inflammatory bowel diseases

2011 ◽  
Vol 34 (8) ◽  
pp. 1040-1042 ◽  
Author(s):  
E. McDermott ◽  
D. Keegan ◽  
B. Hall ◽  
E. N. Mhuruchu ◽  
S. Murphy ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Inflammatory Bowel Diseases ◽  
Thiopurine Therapy ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals Thioguanine Therapy in Inflammatory Bowel Diseases. A Practical Guide

2020 ◽  
Vol 29 (4) ◽  
pp. 637-645
Author(s):  
Femke Crouwel ◽  
Melek Simsek ◽  
Chris J.J. Mulder ◽  
Hans J.C. Buiter ◽  
Nanne K De Boer
Keyword(s):  
Adverse Events ◽  
Inflammatory Bowel Diseases ◽  
Nodular Regenerative Hyperplasia ◽  
Therapy Failure ◽  
Safety Issues ◽  
Thiopurine Therapy ◽  
Routine Monitoring ◽  
Bowel Diseases ◽  
Discontinue Therapy ◽  
Inflammatory Bowel

Thiopurine-derivates azathioprine and mercaptopurine are frequently used to maintain remission in inflammatory bowel diseases (IBD). Despite their efficacy, more than 50% of patients discontinue therapy, mainly due to the development of adverse events. Thioguanine is an alternative thiopurine and has been conditionally licensed in The Netherlands as IBD treatment for patients after conventional thiopurine therapy failure. In this review we will provide practical information on initiating and maintaining thioguanine therapy in IBD and provide information concerning safety issues and future perspectives. The thioguanine toxicity profile is relatively mild and the reported incidence of nodular regenerative hyperplasia related to thioguanine use seems comparable to conventional thiopurines and the background incidence in IBD patients. Routine monitoring of laboratory parameters and adverse events is recommended, comparable to the monitoring of patients on conventional thiopurine therapy.

scholarly journals Epigenetics of Inflammatory Bowel Disease: Unraveling Pathogenic Events

2019 ◽  
Vol 1 (2) ◽  
Author(s):  
Beatriz Mateos ◽  
Cora Palanca-Ballester ◽  
Esteban Saez-Gonzalez ◽  
Inés Moret ◽  
Adrian Lopez ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Clinical Practice ◽  
Inflammatory Bowel Diseases ◽  
Drug Response ◽  
Current Knowledge ◽  
Epigenetic Biomarkers ◽  
Bowel Diseases ◽  
Potential Applicability ◽  
Inflammatory Bowel ◽  
New Biomarkers

Abstract Epigenetics has emerged as a new and promising field in recent years. Because there exists a need to find new biomarkers and improve diagnosis, prognosis, and drug response for inflammatory bowel diseases, the research on epigenetic biomarkers for molecular diagnostics encourages the translation of this field from the bench to the clinical practice. In this review, we present an overview of the current knowledge and its potential applicability of this emerging field in inflammatory bowel diseases.

scholarly journals Glucocorticosteroid therapy in inflammatory bowel diseases: From clinical practice to molecular biology

2017 ◽  
Vol 23 (36) ◽  
pp. 6628-6638 ◽  
Author(s):  
Karen Dubois-Camacho ◽  
Payton A Ottum ◽  
Daniel Franco-Muñoz ◽  
Marjorie De la Fuente ◽  
Alejandro Torres-Riquelme ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Molecular Biology ◽  
Inflammatory Bowel Diseases ◽  
Bowel Diseases ◽  
Inflammatory Bowel

The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice

2008 ◽  
Vol 40 (10) ◽  
pp. 814-820 ◽  
Author(s):  
S. Saibeni ◽  
T. Virgilio ◽  
R. D’Incà ◽  
L. Spina ◽  
A. Bortoli ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Inflammatory Bowel Diseases ◽  
Bowel Diseases ◽  
Inflammatory Bowel

scholarly journals Vedolizumab in patients with inflammatory bowel diseases of in real clinical practice

2020 ◽  
Vol 92 (2) ◽  
pp. 67-73
Author(s):  
M. V. Shapina ◽  
B. A. Nanaeva
Keyword(s):  
Clinical Practice ◽  
Clinical Response ◽  
Inflammatory Bowel Diseases ◽  
Clinical Remission ◽  
Line Therapy ◽  
Steroid Dependent ◽  
Endoscopic Remission ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Real Clinical Practice

Vedolizumab is currently the only selective biological drug for the treatment of inflammatory bowel diseases (IBD). Its effectiveness and safety has been shown in clinical trials. This article presents the experience of using vedolizumab in real clinical practice in patients with various forms of ulcerative colitis (UC) and Crohns disease (CD). Materials and methods.96 patients with IBD (62 with CD and 34 with UC) were prescribed therapy with vedolizumab at a dose of 300 mg intravenously at 0, 2, and 6 weeks, and further maintenance therapy was continued every 8 weeks. Most patients had prolonged inflammation (27 (79.4%) with total UC, 35 patients with CD (56.5%) had ileocolitis), resistance to therapy, including biological drugs (19 (55.9%) in patients with UC and 49 (79.0%) in patients with CD). The effectiveness of therapy was evaluated after 3 months (based on clinical response and clinical remission), 6 and 12 months (endoscopic response and endoscopic remission were additionally evaluated). Results.After 3 months, clinical remission was observed in 62.5% and 36.6%, respectively. After 6 months, these indicators were 66.7% and 61.0%, and after 12 months, 70.8% and 61.0%, respectively. After 6 months, endoscopic remission was observed in 50.0% of UC patients and 26.8% of CD patients. After 12 months, it reached 58.3% and 31.7%, respectively. The analysis showed greater efficacy in bio-naive patients with CD (steroid-free remission after 12 months 62.5%, endoscopic remission 37.5%), as well as patients with non-stricturizing non-penetrating CD (58%). In patients with UC, vedolizumab showed the same effectiveness both in bio-naive patients (70.0%) and as a second-line therapy (71.2%). It turned out to be more effective in patients with moderate UC (76.2%) and steroid-dependent UC (77.8%). Conclusions.Vedolizumab is effective in achieving clinical response and clinical remission, as well as endoscopic response and endoscopic remission in patients with UC and CD. Given the selective mechanism of action of the drug, it can be recommended as a first-line therapy.

Sign in / Sign up

Export Citation Format

Share Document